The study aims to compare retrospectively two combinations for one-step assessment of advanced fibrosis: LIVERFASt Fibrosis & Liver Stiffness Measurement (LSM, Fibroscan) versus FIB-4 & LSM, for the identification of histological advanced fibrosis in patients with Type 2 diabetes (T2D) that undergone liver biopsy (LB).
Combination of LIVERFASt (LF) & Liver Stiffness Measurement (LSM) using Fibroscan outperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)
Combination of LIVERFASt (LF) & Liver Stiffness Measurement (LSM) using Fibroscan outperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)
